A novel strategy to induce penile erection during penile doppler ultrasound: oral sildenafil administration plus alprostadil injection

Figures & data

Table 1. Participant characteristics (N = 60).

	Total (N = 60)	Subgroup 1 (N1 = 30) A→B	Subgroup 2 (N2 = 30) B→A	P value
Age (years)	40.77 ± 6.73	39.77 ± 6.81	41.76 ± 6.61	0.253
IIEF-5	13.42 ± 3.53	13.93 ± 3.23	12.90 ± 3.79	0.260
Testosterone (nmol/L)	13.84 ± 3.83	13.26 ± 3.30	14.42 ± 4.28	0.245
Fasting glucose (mmol/L)	4.97 ± 0.68	5.04 ± 0.66	4.89 ± 0.70	0.386
Total cholesterol (mmol/L)	4.10 ± 1.01	4.33 ± 1.16	3.87 ± 0.91	0.092
Triglycerides (mmol/L)	1.35 ± 0.70	1.46 ± 0.87	1.23 ± 0.48	0.225

Notes: Model A: Injection of 15 μg alprostadil alone; Model B: Oral 100 mg sildenafil administration plus injection of 15 μg alprostadil.

Figure 1. PDU parameters according group and model. (Panel A: maximum PSV; Panel B: minimum EDV; Panel C: RI).

Table 2. PDU parameters between 2 models.

Parameters	Model		P value
	A	B
PSV (cm/s)	37.87 ± 13.37	45.56 ± 15.79	<0.001
EDV (cm/s)	3.31 ± 4.79	1.52 ± 5.46	<0.001
RI	0.89 ± 0.13	0.95 ± 0.11	<0.001
Rigidity, EHS			0.016
EHS I	0	0	–
EHS II	23 (38.3%)	13 (21.7%)	–
EHS III	21 (35.0%)	15 (26.7%)	–
EHS IV	16 (26.7%)	32 (51.7%)	–

Notes: PSV: Peak systolic velocity; EDV: End diastolic velocity; RI: Resistive index; EHS: Erectile hardness score.

Model A: Injection of 15 μg alprostadil alone; Model B: Oral 100 mg sildenafil administration plus injection of 15 μg alprostadil;.

The differences of PDU parameters were compared by paired t-test.

Table 3. Diagnosis classification between 2 models.

Classification	Model		P value
	A	B
AED	19 (31.67%)	9 (15.00%)	0.031
VED	14 (23.33%)	23 (38.33%)	0.075
Mix-ED	14 (23.33%)	5 (8.33%)	0.024
Non-vascular ED	13 (21.67%)	23 (38.33%)	0.066
Total	60 (100.00%)	60 (100.00%)	—

Notes: AED: Arterial erectile dysfunction; VED: Venogenic erectile dysfunction; Mix-ED: Mix erectile dysfunction.

The differences of ED subtype diagnoses were compared by chi-square test.

Table 4. Complications due to different models.

	No. of Model A	No. of Model B
Priapism	4 (14.3%)	5 (16.1%)
Pain	22 (78.6%)	21 (67.7%)
Urethrorrhagia	2 (7.1%)	1 (3.2%)
Dizziness	0	2 (6.5%)
Flushing	0	2 (6.5%)

Notes: Model A: Injection of 15 μg alprostadil alone; Model B: Oral 100 mg sildenafil administration plus injection of 15 μg alprostadil.

Data availability statement

The data used for the present study are available from the corresponding author on reasonable request.